To cite this paper use one of the standards below:
INTRODUCTION AND OBJECTIVES: Glioblastoma (GBM) is the most aggressive tumor of the central nervous system and accounts for around 54% of the astrocytoma cases. GBM's resistance to treatment and tumor recurrence are attributed to subpopulations of tumor stem cells (TSCs), also known as tumor initiator cells, which have capabilities similar to those of normal stem cells, such as self-renewal and adaptation to the microenvironment. Different TSCs subpopulations have already been identified, and their proportion in the tumor mass varies between patients. The aim of this project is to identify differences among tumor stem cell populations present in glioblastoma and to correlate these findings with chemotherapy resistance and tumor heterogeneity in different patients. MATERIAL AND METHODS: We performed primary cell cultures of glioblastoma from biopsies obtained from surgeries at HUCCF. The cells were immunostained for specific tumor stem cell markers such as CD44, CD133, and galectin 3. Additionally, the cells were treated with temozolomide, and cell viability was quantified using the MTT assay. RESULTS AND CONCLUSION: Preliminary results show that glioblastoma cells are resistant to temozolomide (TMZ),as observed in the the cell viability tests (MTT) an average of 20% of glioblastoma cells died in the first 24 hours, and after 48h we observed no changes in the viability of cells treated with TMZ. The 1223 cell line, that was not diagnosed as glioblastoma, was much less resistant to treatment, since 45% of the cells had died, after 48h. Immunocytochemistry analysis revealed the presence of the CD44 protein, which is related to the presence of TSCs. We also identified this technique, Galectina-3, whose expression has also been linked to tumor stem cells as well in cases of brain inflammation and tumor progression. Based on these results, we can conclued that our cell lines have a high percentage of cells that present stem cells markers even before chemotherapy treatment.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper